ReviewMolecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders
Introduction
Dysfunction of cerebral cortex and hippocampus in schizophrenia and related disorders is thought to include alterations in GABAergic, inhibitory neurotransmission (Guidotti et al., 2005, Lewis et al., 2005). The underlying cellular mechanisms include subtle changes in interneuron connectivity (Benes and Berretta, 2001) and a distinct set of molecular and genetic alterations (Harrison and Weinberger, 2005). Among the genes involved in the pathophysiology of cortical dysfunction in schizophrenia is GAD1 (Rapoport et al., 2005), which encodes the 67 kDa isoform of glutamic acid decarboxylase, the key enzyme for GABA synthesis (Bu et al., 1992). Genetic studies linked GAD1 to abnormal neurodevelopment and early (childhood)-onset schizophrenia (Addington et al., 2005, Lundorf et al., 2005) and bipolar disorder (Lundorf et al., 2005). Furthermore, subjects diagnosed with psychosis frequently show dysregulated GAD67 and GAD65 expression in cerebral cortex and other brain regions (Akbarian et al., 1995, Blatt, 2005, Dracheva et al., 2004, Fatemi et al., 2002, Fatemi et al., 2005, Guidotti et al., 2000, Heckers et al., 2002, Torrey et al., 2005, Volk et al., 2000, Woo et al., 2004). As discussed further below, the majority of the studies conducted on postmortem brain tissue from clinical cases report alterations in GAD67 mRNA levels. Therefore, insight into the molecular pathways governing GAD67 gene expression could advance current knowledge on the pathogenesis of psychosis. Studies in animals, complemented by postmortem and other clinical studies, identified several molecular and cellular mechanisms that regulate cortical GAD67 expression. These include changes in neuronal activity, disordered connectivity formation during development, alterations in glutamatergic and dopaminergic neurotransmission and defects in neurotrophin or glycoprotein signaling. This review will summarize, for each of these mechanisms, the relevant findings obtained from animal models and clinical studies. We propose an integrative model to explain GAD67 gene expression changes in psychosis. The model includes allelic polymorphisms in the GAD1 promoter sequence as genetic susceptibility factors, which operate in conjunction with a defined set of maladaptive molecular mechanisms contributing to cortical dysfunction in psychosis.
Section snippets
GAD genes and function
Glutamic acid decarboxylase (GAD) in brain catalyzes synthesis of the inhibitory neurotransmitter gamma-amino butyric acid (GABA). The GABAergic neurons of the mammalian nervous system express two homologous forms of GAD, with protein sizes of 67 and 65 kDa, each encoded by a different gene (Bu et al., 1992, Erlander and Tobin, 1991). It is estimated that GAD67 accounts for 56–85% of the GABA synthesis flux in rat cerebral cortex at baseline (Mason et al., 2001), and up to 80–90% of overall
Altered GAD67 expression in psychosis—functional implications
The initial study on GAD67mRNA expression in prefrontal cortex (PFC) of schizophrenics (Akbarian et al., 1995) was based on a two-fold rationale: First, experiments on visual cortex of cats and non-human primates revealed that GAD67mRNA is heavily regulated by neuronal activity (Benson et al., 1989, Benson et al., 1991). Second, schizophrenia is frequently accompanied by dysfunction and hypoactivity of prefrontal and other cortical areas (Goff and Evins, 1998, Wolkin et al., 1992). Therefore,
Altered GAD65 expression in psychosis
As discussed above, a substantial number of postmortem studies reported significant changes in GAD67 expression in brain of subjects diagnosed with psychosis. A number of studies measured both GAD67 and GAD65 mRNA or protein levels. A comprehensive study by Guidotti et al. (2000) found a deficit in GAD67, but not GAD65 mRNA and protein in prefrontal and cerebellar cortices of schizophrenia and bipolar disorder subjects. In other studies, however, altered levels of GAD67 in cerebral cortex,
Activity-dependent regulation of GAD67 transcription
In visual cortex of non-human primates, a decrease in sensory input from one eye results in a marked reduction of GABA and GAD in ocular dominance columns associated with the deprived eye (Hendry and Jones, 1986). This GABA/GAD effect is apparent within the first 48 h of monocular deprivation (Hendry and Jones, 1986). Because GAD67 mRNA levels appear unchanged within the first 5 days after monocular deprivation (Benson et al., 1991), posttranscriptional mechanisms are thought to be play a
Neurotrophin signaling pathways upstream of GAD67 transcription
The reduction of NMDA receptor-mediated currents is likely to be only one out of several mechanisms by which decreased neuronal activity results in downregulation of GAD67 in cortex of schizophrenics. For example, it is now increasingly recognized that brain-derived neurotrophic factor (BDNF) and its high affinity, receptor, the receptor tyrosine kinase TrkB, are key regulators of inhibitory interneuron function in cerebral cortex and other brain regions. In the cortex, BDNF is synthesized and
Developmental perturbation of cortical connectivity causes long-term changes in GAD67 expression
Brain injuries during the developmental period eventually induce long-lasting changes in the regulation of BDNF and GAD67. For example, excitotoxin-induced ablation of subplate neurons, which comprise a transient population of cells located underneath the developing cortical plate, results in increased levels of BDNF and GAD67 in the overlying cortex for a period lasting at least 6 weeks postinjury (Lein et al., 1999). This observation is of interest, given that some subjects with schizophrenia
Glycoproteins as regulators of GABA/GAD
The neural cell adhesion molecule (NCAM), a member of the immunoglobulin superfamily of molecules, plays an important role for neuronal process outgrowth, synapse formation and signal transduction (Rougon and Hobert, 2003). Intercellular adhesion is regulated by the extracellular region of NCAM (NCAM-EC), which is comprised of immunoglobulin-like and fibronectin III domains (Panicker et al., 2003). Elevated levels of NCAM-EC were reported for the prefrontal cortex and hippocampus of
Regulation of GAD67 and GAD65 expression by antipsychotic drugs
Presently, it is still unclear if the downregulation of cortical GAD67 expression in the clinical samples (Table 1) and in the animal models mentioned above is of relevance for the molecular pathology of schizophrenia and related disorders. If so, one would expect that commonly used therapeutic interventions result in changes opposite to those caused by the disease. Consequently, treatment with antipsychotic drugs would be expected to induce increased expression of GAD67, and possibly also of
Allelic variants of GAD67 confer genetic risk for childhood-onset schizophrenia and bipolar disorder
The 67 kDa isoform of glutamic acid decarboxylase, GAD67, is encoded by GAD1, a gene that resides on the long arm of chromosome 2 (2q31). The GAD1 gene extends across 45 kb of genomic DNA and includes 18 exons (Bu and Tobin, 1994). Addington et al. (2005) examined a group of 72 subjects diagnosed with childhood-onset schizophrenia, a rare subtype of the disorder defined as the onset of psychotic symptoms by age 12 (Nicolson and Rapoport, 1999). They identified a number of adjacent single
An integrative model and future directions
Little is known about the molecular pathology that underlies cortical dysfunction, including defective GABAergic circuitry, in schizophrenia and related disorders. Evidence from postmortem studies and animal models suggests that the GAD67 deficit could result from (i) disordered connectivity formation during development, (ii) alterations in glycoproteins (N-CAM, Reelin) regulating GABAergic synapses, (iii) disruption of neurotrophin signaling pathways (BDNF/TrkB) and (iv) abnormalities in
Acknowledgment
This work was supported by grants from the National Institutes of Health (MH071476 and MH074318-01) to S.A.
References (128)
- et al.
Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects
Schizophr. Res.
(1996) - et al.
Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures
Biochem. Biophys. Res. Commun.
(1996) - et al.
Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins
Biol. Psychiatry
(2002) - et al.
GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder
Neuropsychopharmacology
(2001) - et al.
Glutamate decarboxylase(65)-immunoreactive terminals in cingulate and prefrontal cortices of schizophrenic and bipolar brain
J. Chem. Neuroanat.
(2000) - et al.
Expression of glutamic acid decarboxylase mRNA in normal and monocularly deprived cat visual cortex
Brain Res. Mol. Brain Res.
(1989) GABAergic cerebellar system in autism: a neuropathological and developmental perspective
Int. Rev. Neurobiol.
(2005)- et al.
The exon–intron organization of the genes (GAD1 and GAD2) encoding two human glutamate decarboxylases (GAD67 and GAD65) suggests that they derive from a common ancestral GAD
Genomics
(1994) - et al.
Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia
Brain Res. Brain Res. Rev.
(2000) - et al.
Enhanced dizocilpine efficacy in heterozygous reeler mice relates to GABA turnover downregulation
Neuropharmacology
(2004)